TALAPRO-3 Results: The Era of Talazoparib, Enzalutamide, and ADT in First-Line Prostate Cancer Treatment
In this article
A New First-Line Standard in HRR-Mutant Metastatic Prostate Cancer?
PARP + AR Pathway Blockade Moves to an Earlier Line of Prostate Cancer Treatment
The combination of talazoparib + enzalutamide had previously shown strong efficacy in metastatic castration-resistant prostate cancer, particularly in patients with HRR mutations. What distinguishes TALAPRO-3 is that it moves this strategy to an earlier stage: metastatic castration-sensitive disease. This is biologically highly meaningful, because prostate cancers with HRR defects struggle to repair DNA damage and may be more sensitive to PARP inhibition.
While enzalutamide suppresses androgen receptor signaling, talazoparib targets PARP-mediated DNA repair. Suppressing these two pathways together may provide deeper and longer disease control, particularly in tumors with DNA repair defects. TALAPRO-3 shows that this approach may have value not only in later lines but also while the disease is still hormone-sensitive.
Brief Concept Note: What Are mCSPC, HRR, and a PARP Inhibitor?
mCSPCmeans metastatic castration-sensitive prostate cancer; even though the disease is metastatic, it may still respond to testosterone suppression. HRRstands for homologous recombination repair, one of the cell’s important systems for repairing DNA double-strand breaks. PARP inhibitorstarget DNA repair pathways to promote the accumulation of lethal DNA damage, particularly in tumor cells with HRR defects.
Why Talazoparib + Enzalutamide?
Talazoparib is a potent PARP inhibitor, while enzalutamide blocks androgen receptor signaling. In prostate cancer cells, the androgen receptor pathway and the biology of DNA repair are not entirely independent. Suppressing AR signaling may create vulnerabilities in DNA repair pathways, and PARP inhibition may make these vulnerabilities more pronounced.
The rationale for the combination is therefore not simply to place two effective drugs side by side. The aim is to target two fundamental dependencies of prostate cancer simultaneously: hormonal signaling and DNA repair capacity.
TALAPRO-3: A Double-Blind, Randomized Phase 3 Study of 599 Patients
TALAPRO-3 is an international, double-blind, randomized, placebo-controlled phase 3 study conducted in patients with metastatic castration-sensitive prostate cancer harboring HRR gene alterations. A total of 599 patients were randomized: 300 patients entered the talazoparib + enzalutamide arm and 299 entered the placebo + enzalutamide arm. All patients continued ADT.
The talazoparib dose was 0,5 mg daily, or 0,35 mg in patients with moderate renal impairment. Enzalutamide was given at 160 mg daily in both arms. Patients were stratified by de novo or relapsed disease, high/low-volume disease, and BRCA-mutant / non-BRCA-mutant status.
| Aspect | Talazoparib + enzalutamide | Placebo + enzalutamide | Clinical significance |
|---|---|---|---|
| Number of patients | 300 | 299 | A total of 599 patients with HRR-altered mCSPC were randomized. |
| Treatment | Talazoparib 0,5 mg + enzalutamide 160 mg + ADT | Placebo + enzalutamide 160 mg + ADT | PARP inhibition was added to standard AR pathway suppression. |
| Patient selection | Metastatic castration-sensitive prostate cancer with HRR gene alterations | The study tested biomarker-based precision treatment intensification. | |
| Primary endpoint | Investigator-assessed rPFS | The time without radiological progression or death was evaluated. | |
| Key secondary endpoint | Overall survival | OS has not yet reached statistical significance; follow-up is ongoing. | |
Brief Concept Note: What Is rPFS?
rPFSmeans radiographic progression-free survival. It measures the time without disease progression on imaging or death. Because bone metastases and soft-tissue lesions are assessed together in prostate cancer, rPFS is a very important endpoint in metastatic disease.
rPFS: Median Not Reached vs 45,8 Months
TALAPRO-3 met its primary endpoint. With a median follow-up of approximately 37,6–37,7 months , median rPFS had not yet been reached in the talazoparib + enzalutamide arm; in the placebo + enzalutamide arm, median rPFS was reported as 45,8 months . HR was 0,481, with a 95% confidence interval of 0,357–0,647 and a P value of <0,0001 .
The three-year rPFS rate was %76,6in the talazoparib + enzalutamide arm and %56,2 in the control arm. This shows that PARP + AR pathway blockade during the early metastatic hormone-sensitive phase may significantly prolong disease control.
Clinical Significance of the rPFS Result
- The risk reduction is substantial: HR 0,481 indicates an approximately 52% relative reduction in the risk of radiographic progression or death.
- Median rPFS was not reached: More than half of the patients in the talazoparib arm remained progression-free at the data cutoff.
- The 3-year difference is large: 76,6% vs 56,2% represents a meaningful and clinically appreciable separation early in the disease course.
- Biomarker-based intensification: The benefit becomes more rational when patients with HRR alterations are selected.
The Strongest Benefit Is in Patients With BRCA1/2 Alterations
The rPFS benefit was seen both in patients with BRCA1/2 alterations and in those with non-BRCA HRR alterations. As expected, however, the strongest effect emerged in the BRCA subgroup. In patients with BRCA1/2 alterations, 3-year rPFS was %77,2in the talazoparib arm and %48,8 in the control arm; HR 0,368.
Benefit also persisted in patients with HRR alterations other than BRCA1/2: 3-year rPFS was 76,2% vs 60,2%, HR 0,567. This result suggests that the talazoparib + enzalutamide combination may not be limited to BRCA, although the magnitude of effect is more pronounced in the BRCA group.
| Subgroup | Talazoparib + enzalutamide 3-year rPFS | Control 3-year rPFS | HR | Clinical interpretation |
|---|---|---|---|---|
| Patients with BRCA1/2 alterations | %77,2 | %48,8 | 0,368 | The strongest biological and clinical benefit is seen in this group. |
| Patients with non-BRCA HRR alterations | %76,2 | %60,2 | 0,567 | The benefit is maintained, but the magnitude of effect is more modest than in the BRCA group. |
| Entire HRR-mutant population | %76,6 | %56,2 | 0,481 | The study’s positive primary result is clinically strong across the entire HRR-mutant population. |
Brief Concept Note: Are BRCA and Other HRR Genes the Same?
No. BRCA1/2are the HRR genes from which the most pronounced benefit of PARP inhibitors is expected. ATM, CDK12, CHEK2, PALB2, and other HRR genes may also be involved in DNA repair, but sensitivity to PARP inhibitors is not the same across genes. HRR-mutant patients should therefore be interpreted at the gene level rather than considered to have a single uniform biology.
OS Is Not Yet Significant, but the Trend Favors the Combination
At the interim analysis, overall survival showed a trend favoring talazoparib + enzalutamide but did not reach statistical significance. There were 74 deaths in the talazoparib arm and 91 in the control arm. The three-year OS rate was 77,8% vs 71,6%; HR 0,767, with P=0,0905 reported.
Talazoparib + enzalutamide also improved the time to PSA progression and the time to initiation of subsequent systemic antineoplastic therapy. At three years, the proportion of patients without PSA progression was 78,3% vs 62,7% , while the proportion who had not started subsequent systemic therapy was reported as 78,6% vs 62,0% .
Truecheck Note: OS Is Not Yet Mature
For now, TALAPRO-3 can be interpreted as practice-changing evidence for rPFS, but overall survival has not yet reached statistical significance. When speaking with a patient, it is therefore accurate to say, “It significantly delays disease progression on imaging”; longer follow-up is needed before saying, “It has definitely extended survival.”
The Benefit Is Strong, but There Is a Cost in Hematological Toxicity
As expected, the safety profile of talazoparib + enzalutamide was associated with more substantial hematological toxicity. The rate of grade 3–4 treatment-emergent adverse events was %79in the talazoparib arm and %41 in the control arm. The rate of serious adverse events was reported as %42 and %32 , respectively.
The most common side effects were anemia, fatigue, decreased neutrophils, neutropenia, asthenia, and decreased white blood cells. Anemia occurred in %71 of patients in the talazoparib arm; grade 3–4 anemia was %51 . The rate of adverse events leading to permanent discontinuation of talazoparib was %19, and the rate of discontinuation due to anemia was reported as %5 .
Brief Concept Note: Why Are Anemia and Neutropenia Important?
Anemiais a low hemoglobin level; it may cause weakness, shortness of breath, palpitations, and a need for transfusion. Neutropeniais a decrease in white blood cells important for protection against infections. Because PARP inhibitors can suppress the bone marrow, monitoring the complete blood count is an integral part of treatment.
Practical Safety Note
Although this combination provides a strong rPFS benefit, it may require regular complete blood counts, treatment interruptions, dose reductions, and a transfusion plan when needed, particularly because of anemia and neutropenia. The benefit-risk balance should be assessed more carefully in patients who are older or frail, have low baseline hemoglobin, limited bone marrow reserve, or extensive bone metastases.
From mCRPC to mCSPC: PARP Inhibitors Move to an Earlier Treatment Line
PARP inhibitors first found a place in prostate cancer in metastatic castration-resistant disease. Agents such as olaparib, rucaparib, niraparib, and talazoparib changed the treatment paradigm, particularly in patients with mCRPC harboring BRCA1/2 and certain HRR gene alterations. TALAPRO-2 had already brought the talazoparib + enzalutamide combination strongly into focus in mCRPC.
TALAPRO-3 tests the use of this strategy earlier, in mCSPC. This matters because tumor burden, clonal heterogeneity, and resistance biology are still at a different stage while the disease remains hormone-sensitive. Early intensification in the right patient selected by biomarkers may meaningfully change long-term disease control.
| Study / era | Patient group | Treatment approach | Key message | Relationship to TALAPRO-3 |
|---|---|---|---|---|
| The era of PARP inhibitor monotherapy | HRR-mutant mCRPC | PARP inhibitor, particularly in patients with BRCA alterations | Targeted treatment gained value in prostate cancer with DNA repair defects. | Established the clinical significance of HRR biomarkers. |
| TALAPRO-2 | mCRPC | Talazoparib + enzalutamide | PARP + AR pathway blockade in mCRPC was strengthened by rPFS data and, later, OS data. | Validated the rationale for the combination in a later line. |
| TALAPRO-3 | HRR-mutant mCSPC | Talazoparib + enzalutamide + ADT | HR 0,481 for rPFS; a stronger benefit in the BRCA group. | Brings the precision intensification strategy to the first line. |
HRR Testing Is Becoming Even More Critical at mCSPC Diagnosis
The most practical consequence of TALAPRO-3 is that it further reinforces the need for HRR testing at the start of treatment in metastatic castration-sensitive prostate cancer. If HRR status is established late, a patient may miss the opportunity for biomarker-based first-line intensification.
The ability to perform testing not only in tumor tissue but also, when appropriate, using ctDNA is practically important. However, the distinction between germline and somatic alterations must also be assessed. BRCA1/2, PALB2, ATM, CDK12, and other HRR genes may have different implications for treatment selection, family counseling, and genetic risk management.
Brief Concept Note: What Is the Difference Between Germline and Somatic Mutations?
A germline mutationis a genetic alteration present from birth that may be inherited within a family. A somatic mutationis an alteration acquired later only in tumor cells. In prostate cancer, certain HRR alterations, such as BRCA1/2, may affect both treatment selection and the need for genetic counseling of family members.
Practical Lessons That Can Be Drawn Today
- Early molecular testing in mCSPC is essential: HRR status should be known at the start of treatment.
- The BRCA subgroup is particularly important: The strongest rPFS benefit is seen in patients with BRCA1/2 alterations.
- Non-BRCA HRR should not be excluded: There is also benefit in this group, although the magnitude of effect is more modest.
- OS should be awaited: The rPFS data are strong, but overall survival is not yet significant.
- Toxicity management should be planned: Anemia, neutropenia, and dose modifications should be discussed from the outset.
- Patient selection should be personalized: The balance between biological benefit and hematological toxicity should be assessed for each patient.
How Should This Be Discussed With the Patient?
“If one of the DNA repair genes in your prostate cancer is defective, this may make the cancer cells more sensitive to drugs called PARP inhibitors. In TALAPRO-3, adding talazoparib to enzalutamide significantly delayed disease progression on imaging. The benefit appears stronger, particularly in patients with BRCA alterations. However, this treatment may increase side effects such as anemia and decreases in blood cells, so regular blood counts and dose adjustments may be needed.”
The Era of Precision First-Line Treatment Is Beginning
Academic Assessment
TALAPRO-3 is a practice-changing study that provides a strong example of biomarker-based first-line treatment intensification in HRR-mutant metastatic castration-sensitive prostate cancer.
The benefit at an rPFS HR of 0,48 and the even more pronounced effect in the BRCA subgroup show that PARP inhibitors may now play an important role not only in later-line mCRPC but also in the earlier hormone-sensitive stage of the disease.
However, this approach should not mean “more treatment for every patient with mCSPC.” The most appropriate clinical message is a personalized first-line strategy that takes into account early HRR testing, the distinction between BRCA and non-BRCA, management of hematological toxicity, and maturation of OS data.
New Clinical Questions After TALAPRO-3
TALAPRO-3 provided strong rPFS data, but several important issues need further clarification to establish the true clinical position of this treatment. Most importantly, OS data must mature, and we need a better understanding of which HRR gene alterations yield the highest net clinical benefit.
Open Questions
- Will an OS advantage emerge? The 3-year OS trend is favorable but has not yet reached statistical significance.
- Do non-BRCA HRR genes behave in the same way? PARP sensitivity may differ for ATM, CDK12, CHEK2, PALB2, and other genes.
- What will its role be alongside triplet strategies? How will its clinical position be determined relative to ADT + ARPI + docetaxel or abiraterone-based intensification?
- What should the treatment sequence be? How will using a PARP inhibitor in mCSPC affect subsequent options in mCRPC?
- How will anemia management be optimized? Algorithms for transfusion, dose reduction, and treatment interruption will be critical in real-world practice.
- How will germline counseling be integrated? BRCA and other inherited HRR alterations may also have implications for family members.
Truecheck Note
The rPFS result of TALAPRO-3 is strong and practice-changing, but overall survival is not yet mature. The combination also carries a substantial hematological toxicity burden. The treatment decision should therefore be based not only on HRR positivity but also on the gene subtype, the patient’s age, bone marrow reserve, comorbidities, symptom burden, metastatic disease volume, and patient preference.
TALAPRO-3: A New Threshold for Precision Treatment Intensification in mCSPC
TALAPRO-3 showed that, in metastatic castration-sensitive prostate cancer harboring HRR gene alterations, talazoparib + enzalutamide + ADT significantly prolonged radiographic progression-free survival compared with enzalutamide + ADT. Median rPFS was not reached in the talazoparib arm, whereas it was 45,8 months in the control arm; HR 0,481 and P<0,0001 were reported.
The benefit was particularly pronounced in patients with BRCA1/2 alterations: 3-year rPFS of 77,2% versus 48,8% and HR 0,368. Benefit was also present in non-BRCA HRR alterations, although the effect was more modest. This distinction shows that the term “HRR-positive” in prostate cancer needs more detailed interpretation at the gene level.
Although OS data have not yet reached significance, the strong results for rPFS, PSA progression, and the time to initiation of subsequent systemic therapy make TALAPRO-3 a candidate for a new precision first-line standard in HRR-mutant mCSPC. The most important message for future clinical practice is clear: in metastatic castration-sensitive prostate cancer, molecular testing should be performed at the start of treatment, not after treatment.
Sources
- OncoDaily. TALAPRO-3 at ASCO 2026: Talazoparib Plus Enzalutamide Improves rPFS in HRR-Deficient mCSPC. 2026.
- Agarwal N et al. PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer. New England Journal of Medicine. 2026.
- ASCO 2026. TALAPRO-3: Talazoparib + enzalutamide compared with placebo + enzalutamide for metastatic castration-sensitive prostate cancer harboring HRR gene alterations.
- Agarwal N et al. TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. Future Oncology. 2024.
- drozdogan.com. A New Era in Prostate Cancer Treatment With Talazoparib and Enzalutamide.
- drozdogan.com. Talazoparib and Enzalutamide Received FDA Approval for Advanced Prostate Cancer With HRR Gene Mutations.
- drozdogan.com. Talazoparib – Overall Survival Results in First-Line Prostate Cancer Treatment.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.